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OBJECTIVES We sought to characterize the predictors of incident congestive heart failure (CHF), as
determined by central adjudication, in a community-based elderly population.
BACKGROUND The elderly constitute a growing proportion of patients admitted to the hospital with CHF,
and CHF is a leading source of morbidity and mortality in this group. Elderly patients differ
from younger individuals diagnosed with CHF in terms of biologic characteristics.
METHODS We analyzed data from the Cardiovascular Health Study, a prospective population-based
study of 5,888 elderly people .65 years old (average 73 6 5, range 65 to 100) at four
locations. Multiple laboratory measures of cardiovascular structure and function, blood
chemistries and functional assessments were obtained.
RESULTS During an average follow-up of 5.5 years (median 6.3), 597 participants developed incident
CHF (rate 19.3/1,000 person-years). The incidence of CHF increased progressively across
age groups and was greater in men than in women. On multivariate analysis, other
independent predictors included prevalent coronary heart disease, stroke or transient ischemic
attack at baseline, diabetes, systolic blood pressure (BP), forced expiratory volume 1 s,
creatinine .1.4 mg/dl, C-reactive protein, ankle-arm index ,0.9, atrial fibrillation, electro-
cardiographic (ECG) left ventricular (LV) mass, ECG ST-T segment abnormality, internal
carotid artery wall thickness and decreased LV systolic function. Population-attributable risk,
determined from predictors of risk and prevalence, was relatively high for prevalent coronary
heart disease (13.1%), systolic BP $140 mm Hg (12.8%) and a high level of C-reactive
protein (9.7%), but was low for subnormal LV function (4.1%) and atrial fibrillation (2.2%).
CONCLUSIONS The incidence of CHF is high in the elderly and is related mainly to age, gender, clinical and
subclinical coronary heart disease, systolic BP and inflammation. Despite the high relative risk
of subnormal systolic LV function and atrial fibrillation, the actual population risk of these for
CHF is small because of their relatively low prevalence in community-dwelling elderly people.
(J Am Coll Cardiol 2000;35:1628–37) © 2000 by the American College of Cardiology
Congestive heart failure (CHF) is a leading source of
morbidity and mortality in the elderly (1–5). Moreover,
elderly patients represent an increasing proportion of pa-
tients with CHF. The reasons for this include aging of the
American population (6), a progressive increase in the age of
onset of CHF (5) and improved treatment of and survival
from cardiovascular diseases, including myocardial infarc-
tion and hypertension. Importantly, elderly patients with
CHF differ from younger patients with CHF (7–9) in terms
of several biologic characteristics, including the relatively
large proportion of elderly patients with CHF who have
preserved systolic function (3,10).
The Cardiovascular Health Study (CHS) is a prospective,
community-based, epidemiologic, observational study of
5,888 participants $65 years old from four different loca-
tions of the U.S. (11). The study was designed to investigate
the risk factors for cardiovascular death and morbidity. This
project contains an extensive array of physiologic and
clinical functional measures, offering the opportunity to
investigate the association of these measures with clinical
events. The purpose of this report is describe the demo-
From the *Division of Cardiology, Georgetown University Hospital, Washington,
DC, and St. Francis Hospital, Roslyn, New York; †Department of Biostatistics,
Washington University, Seattle, Washington; ‡Division of Cardiology, University of
Massachusetts Medical Center, Worcester, Massachusetts; §Department of Radiol-
ogy, Tufts–New England Medical Center, Boston, Massachusetts; \Colchester
Research Facility, University of Vermont, Colchester, Vermont; ¶Wake Forest
University, Winston-Salem, North Carolina; #University of California at Irvine,
Irvine, California; **Division of Cardiovascular Medicine, University of California at
Davis, Davis, California; and ††Division of Epidemiology and Clinical Applications,
National Heart, Lung, and Blood Institute, Bethesda, Maryland. This study was
supported by contracts NO1-HC-85079-85086 and NO1-HC-15103 from the
National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda,
Maryland.
Manuscript received April 2, 1999; revised manuscript received December 7, 1999,
accepted January 19, 2000.
Journal of the American College of Cardiology Vol. 35, No. 6, 2000
© 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00
Published by Elsevier Science Inc. PII S0735-1097(00)00582-9
graphic, functional, anatomic and biochemical predictors of
incident CHF in elderly subjects with and without prevalent
coronary heart disease at enrollment.
METHODS
Subjects. The CHS cohort was obtained from Medicare
eligibility lists at four locations. Participants were recruited
from and examined at the four field centers—Forsyth
County, North Carolina; Sacramento County, California;
Allegheny County, Pennsylvania; and Washington County,
Maryland. The eligible participants included noninstitu-
tionalized, community-dwelling individuals age 65 to 100
(mean [6SD] 73.3 6 5.7 years in men and 72.5 6 5.5 years
in women) who were expected to remain in the defined
geographic area for at least three years. Prevalent coronary
heart disease and stroke were not exclusions from study
enrollment. An original cohort of 5,201 individuals was
recruited in 1989 to 1990 and a second cohort of 687
African-Americans was recruited in 1992 to 1993, giving a
total of 5,888 participants (2,495 men and 3,393 women).
This report examines events through June 1996.
The design, rationale and examination details of the
CHS, initiated and supported by the National Heart, Lung,
and Blood Institute, have been published elsewhere (11).
Briefly, interviews and questionnaires were used to obtain
information on medications, functional status, quality of
life, physical activity, nutrition and medical history. Partic-
ipants reported to the CHS field center clinic after a 12-h
overnight fast for assessment of blood chemistries, blood
pressure (BP), heart rate and cognitive function, as well as
anthropometric, electrocardiographic, echocardiographic,
carotid artery ultrasound and other objective measurements
(11).
Study group. To determine the relation between incident
CHF and baseline demographic, clinical and laboratory
variables, analyses were performed of the entire cohort
without prevalent CHF (n 5 5,625), as determined by
adjudication of clinical records (see the following para-
graph). Additional subgroup analyses were performed for
participants with and without coronary heart disease at
baseline (n 5 973 and 4,652, respectively). Echocardio-
grams were obtained during the baseline examination for
the original cohort (1989 to 1990) and again for surviving
members of both cohorts in 1994 to 1995.
Adjudication of CHF. Methods used to assess cardiovas-
cular events, including CHF, have been reported previously
in detail (12,13). Potential clinical outcome events were
identified at semi-annual visits. Self-report of a physician
diagnosis of CHF was followed by confirmational review of
the participant’s medical records. The presence of CHF was
determined from both the diagnosis of CHF by a physician
and treatment of CHF (i.e., a current prescription for a
diuretic agent and either digitalis or a vasodilator). In
addition, symptoms, signs and chest X-ray findings of CHF
were reviewed by the CHS Events Committee, which
classified all cardiovascular events. Congestive heart failure
was termed “probable” rather than “definite” if the data were
incomplete or unclear from the medical record or, more
rarely, if the data were ambiguous. For cases of fatal CHF,
the underlying cause of CHF (e.g., ischemic, valvular heart
disease) was coded as the cause of death.
Electrocardiography. Twelve-lead electrocardiograms
(ECGs) were obtained at baseline examination and yearly
thereafter. Methods of analysis and classification by the
ECG core laboratory (EPICARE Center, Winston-Salem,
North Carolina), including estimation of left ventricular
(LV) mass, have been published elsewhere (14–17). The
prevalence and kinds of ECG abnormalities at baseline in
this cohort have been previously reported (18).
LV function. Global LV systolic function was qualitatively
assessed from the baseline two-dimensional echocardiogram
as showing normal, borderline or subnormal ejection frac-
tion. Left ventricular function was scored in 99% of the
original CHS cohort, with inter-reader agreement in 94%
and intrareader agreement in 98% of paired studies (19). For
comparison with the clinical evaluation of LV function,
qualitatively assessed normal LV function on the echocar-
diogram approximately corresponds to an ejection fraction
$55%. Analyses were performed on the entire cohort using
baseline LV function as a covariate for the prediction of
incident CHF.
Clinical assessments and measurements. Prevalent coro-
nary heart disease was determined by the participant’s report
of physician diagnosis of angina pectoris, myocardial infarc-
tion, coronary artery bypass graft surgery or percutaneous
transluminal coronary angioplasty before the initial evalua-
tion. Diabetes mellitus was defined by self-report or by the
current use of insulin or an oral hypoglycemic medication.
Hypertension status was characterized as normal, borderline
or definite. Borderline hypertension was defined by systolic
BP $140 but ,160 mm Hg or diastolic BP $90 but
,95 mm Hg. Definite hypertension was defined by systolic
BP $160 mm Hg or diastolic BP $95 mm Hg or a clinical
history of hypertension requiring an antihypertensive med-
ication. The ankle-arm index (i.e., the ratio of supine
systolic ankle to brachial BP), a measure of lower extremity
Abbreviations and Acronyms
BP 5 blood pressure
CHF 5 congestive heart failure
CHS 5 Cardiovascular Health Study
ECG 5 electrocardiogram or electrocardiographic
FEV1 5 forced expiratory volume in 1 s
FVC 5 forced vital capacity
LV 5 left ventricle or ventricular
TIA 5 transient ischemic attack
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arterial occlusive disease, was obtained as described previ-
ously (8). Analyses of fasting serum chemistry values, fasting
lipid values and plasma fibrinogen levels were performed by
the core blood laboratory (University of Vermont, Colches-
ter). Measures of pulmonary function included forced vital
capacity (FVC) and forced expiratory volume in 1 s (FEV1).
Common and internal carotid artery intimal-medial thick-
ness, markers of atherosclerosis (20), were measured at
baseline. Cognitive function was assessed using a Mini-
Mental score obtained by observation of administered men-
tal tasks (21).
Independent variables that were analyzed for their rela-
tion to incident CHF included demographic and clinical
variables (age, gender, race, educational level, income,
height, body weight, BP, ankle-arm index, smoking history,
hypertension history, diabetes history, history of chronic
obstructive pulmonary disease, stroke, transient ischemic
attack [TIA], intermittent claudication), clinical chemistry
values (fasting serum glucose levels, serum insulin, choles-
terol, high and low density lipoproteins, serum creatinine),
coagulation and inflammation variables (factor VII, fibrin-
ogen, albumin, C-reactive protein), carotid ultrasound
(common and internal carotid artery intimal-medial wall
thickness), functional variables (Mini-Mental score, FEV1,
FVC), ECG variables (presence of LV hypertrophy, esti-
mated LV mass, atrial fibrillation, minor and major ST
segment changes, Q wave myocardial infarction) and the
echocardiographic categoric variable for LV systolic func-
tion at baseline.
Statistical methods. Incidence rates for CHF were calcu-
lated in units of person-years due to differences in follow-up
times between the original and new cohorts. Statistical
significance of observed differences in rates across levels of
categoric variables was determined by unadjusted Cox
survival models. Bivariate differences in mean values by
CHF status for continuously measured risk factors were
assessed by t tests.
Cox proportional hazards models were used to identify
risk factors for incident CHF in multivariate models for all
participants free of CHF at entry, and then stratified by
coronary heart disease status at baseline. The models were
generated in stages, with demographic, history, laboratory
and clinic examination measures taken first, followed by
measures of subclinical disease, including ankle arm index,
carotid artery wall thicknesses, ECG abnormalities and LV
systolic function. Once significant predictors were identi-
fied, time-dependent variables (i.e., new or recurrent angina
or myocardial infarction) were added to each model to
evaluate the risk of new episodes of coronary disease on
CHF. In the group without coronary heart disease at
baseline, incident coronary heart disease was added, and in
the group with coronary heart disease at baseline, the
occurrence of a new MI was added. At each stage, stepwise
selection was used with a p value of 0.05. Interactions
between significant variables and gender, race and prevalent
coronary artery disease were examined. When significant
linear relations were identified for continuously measured
risk factors, quintiles of the risk factor based on the CHF
cases were examined to explore the relation of the risk factor
to CHF. If all of the risk appeared to be confined to an
upper quintile, the upper quintile cut point was used to
calculate an indicator variable. Because covariates that have
a high relative risk may have little population impact if the
prevalence of the covariate in the population is low, the
population-attributable risk was computed (22). This cal-
culation combines the prevalence of a risk factor with its
relative risk to estimate that risk factor’s contribution to the
incidence of a clinical end point in the population as a
whole. To calculate the prevalence of risk factors measured
on a continuous scale, these risk factors were dichotomized,
with a clinically relevant cut point chosen when known. The
cut point for the internal carotid artery thickness is the 80th
percentile point, and for low FEV1 it is the lower limit of
normal from published reference equations that provide
predicted FEV1 as a function of age and height for gender
and race subgroups (23,24).
RESULTS
Incidence rates of CHF (Tables 1 and 2). Of 5,625
participants at risk, there were 597 incident cases of CHF
over a median follow-up of 6.3 years, resulting in an
incidence rate of CHF of 19.3/1,000 person-years. The
unadjusted incidence rate of CHF was greatest at the
Washington County site (23.6 vs. Forsyth County 17.5,
Sacramento County 17.5 and Allegheny County 19.3 per
1,000 person-years) (p 5 0.03), primarily because of the
older age of the participants at the Washington County site.
However, the clinic difference was no longer significant after
adjustment for age, gender and coronary heart disease at
baseline. Incidence by gender, age grouping and race is
shown in Table 1 for participants with and without preva-
lent coronary heart disease at baseline. Men had almost
twice the CHF incidence rate as women, and the incidence
rate was markedly greater in those with than in those
without prevalent coronary heart disease, irrespective of age,
gender or race. The incidence of CHF increased across age
groups from 10.6/1,000 person-years in participants 65 to
69 years old at the initial evaluation to 42.5/1,000 person-
years in those participants $80 years old. There were no
racial differences in incident CHF (18.8/1,000 person-years
for African-Americans vs. 19.4/1,000 person-years for non–
African-Americans). The incidence rates of CHF for se-
lected risk factors are presented separately by gender (Table
2). Diabetes status, stroke or TIA, hypertension status
(normal, borderline, definite), intermittent claudication,
ankle-arm index, atrial fibrillation, minor and major ST-T
segment changes, LV function, chronic obstructive lung
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disease, income, educational status and self-perceived gen-
eral health were all associated with the incidence rate of
CHF in both men and women. Smoking was associated
with the incidence rate of CHF only in men.
Baseline biomedical variables. The values for biomedical
variables of interest measured at baseline in men and
women, with and without subsequent CHF, are shown in
Table 3. In comparison with men and women who did not
develop CHF during follow-up, men and women with
incident CHF were older, less educated and slightly shorter
and had a higher systolic BP (but no difference in diastolic
BP), greater LV mass, greater common and internal carotid
artery intimal-medial wall thickness, lower ankle-arm index,
lower FVC and FEV1, higher serum fibrinogen, higher
C-reactive protein, higher fasting plasma glucose and higher
serum insulin. Pack-years of cigarette smoking was greater
in men with incident CHF and displayed a similar trend in
women. Mental acuity was lower at baseline in men with
incident CHF and showed a similar trend in women. Total
cholesterol at baseline was lower in women, and high
density lipoprotein fraction of cholesterol was lower in men
and women with incident CHF than in those without
CHF. On bivariate analyses, self-report of estrogen use was
negatively associated with CHF incidence (incidence 16.9/
1,000 patient-years for those who never used it vs. 10.9 for
past users and 12.0 for current users) (p 5 0.007). However,
after adjustment for age, estrogen use became nonsignificant
(p 5 0.17).
Multivariate analyses. In a model incorporating demo-
graphic features, BP, lung function and blood chemistries,
age, male gender, clinically evident coronary heart disease at
baseline, stroke or TIA at baseline, diabetes, systolic BP,
FEV1 (inverse), creatinine and C-reactive protein were all
independently associated with subsequent CHF. These
associations persisted even after exclusion of prevalent
coronary heart disease in a subgroup analysis. However,
when the analysis was restricted to those with prevalent
coronary heart disease, stroke or TIA at baseline and
baseline systolic BP were no longer independently predictive
of CHF.
Table 4 shows the results of a multivariate analysis that
added measures of subclinical atherosclerotic disease (ankle-
arm index, intimal-medial carotid artery wall thickness),
ECG measures (LV mass, repolarization abnormality, atrial
fibrillation) and echocardiographic estimation of LV systolic
function to the previous demographic, BP and blood chem-
istry variables. For the model including all participants, the
initial demographic and other variables retained signifi-
cance. Moreover, subclinical atherosclerosis, atrial fibrilla-
tion, ST-T segment abnormalities and diminished systolic
function were also independently predictive of incident
CHF.
In the subgroup analysis restricted to participants with
prevalent coronary heart disease, stroke or TIA at baseline,
systolic BP, C-reactive protein, atrial fibrillation, minor
ST-T segment abnormality and carotid artery intimal-
medial thickness were no longer independently predictive of
incident CHF.
New occurrence of coronary heart disease and incident
CHF. Of the 397 incident CHF cases in the subgroup with
no coronary heart disease at baseline, 174 (43.8%) had a new
occurrence of clinically evident coronary heart disease (i.e.,
angina pectoris, myocardial infarction, coronary artery by-
pass graft surgery or coronary angioplasty) before or con-
current with their episode of CHF. The analysis showed a
very large relative risk (13.8; confidence interval [CI] 10.9 to
Table 1. Congestive Heart Failure Incidence Rates per 1,000 Person-Years
All Subjects CHD at Baseline No CHD at Baseline
Subjects
With CHF n
Incidence
Rate
Subjects
With CHF n
Incidence
Rate
Subjects
With CHF n
Incidence
Rate
Race*
Non-black 536 4,762 19.4% 184 831 42.0% 352 3,932 15.1%
Black 61 863 18.8% 16 142 32.7% 45 720 16.4%
Gender†
Female 268 3,257 14.6% 72 446 31.8% 196 2,811 12.2%
Male 329 2,368 26.2% 128 527 49.1% 201 1,841 20.2%
Age‡ (years)
65–69 121 1,961 10.6% 40 277 26.6% 81 1,684 8.2%
70–74 172 1,799 17.2% 53 295 34.8% 119 1,504 14.0%
75–80 157 1,127 26.3% 57 241 49.7% 100 886 20.7%
$80 147 738 42.5% 50 160 71.3% 97 578 35.1%
Overall§ 597 5,625 19.3% 200 973 41.0% 397 4,652 15.3%
*Race was not significant. †Gender was significant at p , 0.0001 in the subjects and non-CHD groups and at p 5 0.003 in the CHD group. ‡Age was significant at p , 0.0001
in all three groups. §The difference in the overall rates for CHD versus non-CHD was significant at p , 0.0001.
CHD 5 coronary heart disease; CHF 5 congestive heart failure.
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Table 2. Congestive Heart Failure Incidence Rates per 1,000 Person-Years for Selected Risk Factors
Baseline Risk Factors
Women Men
Subjects
With CHF n
Incidence
Rate
Subjects
With CHF n
Incidence
Rate
Smoking p 5 0.88 p 5 0.026
Never 149 1,849 14.3% 107 760 26.5%
Former 86 996 15.3% 174 1,337 24.3%
Current 33 409 14.5% 48 265 36.9%
Diabetes status p , 0.0001 p , 0.0001
Normal 192 2,761 12.1% 235 1,901 22.9%
Fasting glucose $126 mg/dl 23 163 26.2% 26 147 35.4%
History of diabetes 53 333 32.5% 68 320 44.6%
Stroke or TIA p 5 0.0001 p , 0.0001
No 246 3,129 13.9% 287 2,193 24.5%
Yes 22 128 35.5% 42 175 52.1%
Hypertension status p , 0.0001 p , 0.0001
Normal 67 1,307 8.5% 107 1,050 18.4%
Borderline* 34 464 13.0% 61 368 31.6%
Definite† 167 1,486 21.2% 161 950 33.6%
Claudication p , 0.0001 p , 0.0001
No 252 3,218 13.9% 304 2,285 25.0%
Yes 16 39 87.7% 25 83 65.3%
Ankle-arm index #0.9 p , 0.0001 p , 0.0001
No 193 2,789 12.0% 229 2,008 20.9%
Yes 63 371 35.1% 91 325 65.4%
Atrial fibrillation on ECG p , 0.0001 p 5 0.0005
No 254 3,199 14.1% 310 2,298 25.4%
Yes 14 51 53.9% 19 67 57.4%
Silent MI p 5 0.03 p 5 0.0026
No 255 3,160 14.3% 308 2,277 25.4%
Yes 13 97 26.3% 21 91 49.4%
Minor ST-T segment changes p , 0.0001 p 5 0.0002
No 184 2,592 12.4% 252 1,971 23.8%
Yes 72 540 25.2% 62 323 39.6%
Major ST-T segment changes p , 0.0001 p 5 0.01
No 221 2,936 13.3% 290 2,178 24.9%
Yes 36 209 33.4% 24 121 42.1%
LV function at baseline p , 0.0001 p , 0.0001
Normal/borderline 228 2,787 13.6% 276 2,011 24.3%
Abnormal 12 33 82.6% 37 101 95.4%
COPD p 5 0.01 p 5 0.035
No 172 2,334 13.1% 252 1,907 24.8%
Yes 94 918 18.2% 76 458 32.5%
Income $$25,000 p 5 0.0002 p , 0.0001
No 193 1,999 17.7% 196 1,212 31.9%
Yes 62 1,004 10.4% 115 1,046 19.7%
High school graduate p , 0.0001 p , 0.0001
No 103 929 20.9% 118 699 35.0%
Yes 164 2,319 12.3% 210 1,662 23.0%
General health p , 0.0001 p , 0.0001
Excellent 17 425 6.6% 35 358 16.9%
Very good 57 818 11.9% 57 581 17.4%
Good 87 1,201 12.6% 125 904 26.2%
Fair 85 683 24.0% 93 447 44.5%
Poor 19 123 37.1% 18 72 59.3%
*Systolic blood pressure (BP) $140 but ,160 mm Hg or diastolic BP $90 but ,95 mm Hg. †Systolic BP $160 mm Hg or diastolic BP $95 mm Hg or a history of hypertension
requiring antihypertensive medications.
The p values were obtained using the unadjusted Cox model.
CHF 5 congestive heart failure; COPD 5 chronic obstructive lung disease; ECG 5 electrocardiogram; LV 5 left ventricular; MI 5 myocardial infarction; TIA 5 transient
ischemic attack.
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17.4) of incident coronary heart disease in the prediction of
CHF. A similar risk was found for the occurrence of a new
myocardial infarction as predictive of CHF in the subgroup
with coronary heart disease at baseline. In participants with
baseline coronary heart disease, of 200 patients with inci-
dent CHF, 53 (26.5%) had a new myocardial infarction
before or concurrent with their first episode of CHF.
Hence, multivariate analyses were performed to adjust for
incident coronary heart disease in those without prevalent
coronary heart disease and for new or recurrent myocardial
infarctions in those with prevalent coronary heart disease. In
participants without prevalent coronary heart disease, ad-
justment for incident coronary heart disease occurring be-
fore incident CHF led to a loss of significance of stroke or
TIA at baseline and a history of diabetes as predictors of
incident CHF. In participants with prevalent coronary heart
disease, myocardial infarction at baseline was predictive of
incident CHF, and because it is also predictive of recurrent
myocardial infarction, its relative risk decreased after adjust-
ment for a new myocardial infarction. The inclusion of a
new myocardial infarction resulted in a loss of predictive
significance for male gender.
LV systolic function and CHF. LV FUNCTION BEFORE
THE ONSET OF CHF. Of the 597 cases of incident CHF, LV
systolic function on the echocardiogram was determined in
553 at baseline examination, 504 (91%) of whom had intact
systolic function before incident CHF and 49 (9%) of whom
had depressed LV function. Of 240 women with evaluable
echocardiograms who developed CHF, 228 (95%) had
intact systolic LV function at baseline. In contrast, of 313
men with incident CHF and evaluable baseline echocardio-
grams, 276 (88%) had intact systolic LV function (p 5
0.006, men vs. women).
PREDICTIVE VALUE OF BASELINE LV FUNCTION FOR INCI-
DENT CHF. The relative risk of CHF in participants with
abnormal baseline LV function in the absence of prevalent
CHF was 2.84 (CI 1.63 to 4.93); in those with prevalent
coronary disease it was 2.11 (CI 1.34 to 3.32). The
association of abnormal LV function with subsequent CHF
was present both in participants with and those without
prevalent coronary heart disease. The relation persisted after
adjustment for LV mass and other ECG covariates, after
adjustment for incident coronary heart disease in partici-
Table 3. Comparison of Biomedical Variables and Incident Congestive Heart Failure
Men Women
CHF No CHF
p
Value CHF No CHF
p
Value
Age (yrs) 75.4 (6.2) 72.8 (5.5) ,0.001 75.1 (6.3) 72.2 (5.3) ,0.001
Education (yrs) 11.9 (3.5) 12.5 (3.4) 0.005 11.5 (3.1) 12.2 (3.0) ,0.001
Standing height (cm) 172.2 (6.6) 173.3 (6.6) 0.008 158.5 (6.2) 158.9 (6.3) 0.265
Sitting height (cm) 88.4 (4.1) 89.2 (4.1) 0.001 81.6 (4.4) 82.1 (4.1) 0.028
Weight (lb) 174.1 (25.5) 174.8 (27.8) 0.681 152.6 (35.8) 149.2 (30.7) 0.094
Diastolic BP (mm Hg) 71.8 (11.9) 72.4 (11.3) 0.398 70.0 (12.0) 70.0 (11.1) 0.881
Systolic BP (mm Hg) 139.7 (21.8) 135.4 (20.8) 0.001 144.2 (22.4) 136.4 (21.9) ,0.001
Smoking (pack-years) 30.4 (33.5) 25.2 (31.0) 0.006 14.1 (22.5) 11.7 (20.9) 0.078
Mini-mental score 27.0 (2.9) 27.4 (2.9) 0.030 27.4 (2.9) 27.7 (2.6) 0.062
ECG LV mass (g) 184.7 (40.2) 173.5 (28.5) ,0.001 145.8 (36.1) 136.8 (23.6) ,0.001
Common carotid artery IM wall thickness
(mm)
1.19 (0.26) 1.10 (0.22) ,0.001 1.09 (0.21) 1.02 (0.20) ,0.001
Internal carotid artery IM wall thickness (mm) 1.76 (0.62) 1.53 (0.57) ,0.001 1.51 (0.60) 1.32 (0.52) ,0.001
Ankle-arm index 1.00 (0.22) 1.10 (0.19) ,0.001 1.00 (0.19) 1.06 (0.15) ,0.001
FEV1 (liters) 2.23 (0.65) 2.48 (0.69) ,0.001 1.57 (0.45) 1.79 (0.47) ,0.001
FVC (liters) 3.33 (0.77) 3.62 (0.79) ,0.001 2.21 (0.52) 2.48 (0.58) ,0.001
Cholesterol (mg/dl) 197.9 (37.7) 198.7 (35.4) 0.703 219.0 (38.7) 221.9 (38.7) 0.243
LDL (mg/dl) 124.0 (34.4) 123.9 (32.9) 0.993 132.6 (36.3) 135.3 (36.7) 0.254
HDL (mg/dl) 45.9 (12.2) 48.1 (12.9) 0.004 57.2 (16.2) 59.5 (15.9) 0.025
Fibrinogen (mg/dl) 330.0 (71.3) 317.7 (67.0) 0.002 333.7 (72.1) 323.9 (64.7) 0.019
Factor VII (%)* 113.9 (27.1) 112.2 (24.2) 0.247 132.9 (35.0) 131.9 (29.2) 0.581
CRP (mg/liter) 4.11 (5.68) 3.35 (6.85) 0.03 5.48 (9.39) 3.41 (5.25) ,0.001
Fasting glucose (mg/dl) 120.8 (42.5) 111.9 (34.4) ,0.001 123.5 (63.0) 107.5 (32.9) ,0.001
Serum insulin (uU/ml) 22.7 (45.4) 15.8 (18.7) ,0.001 21.0 (40.7) 16.1 (21.9) 0.001
Creatinine (mg/dl) 1.31 (0.4) 1.22 (0.4) ,0.001 1.02 (0.5) 0.93 (0.3) ,0.001
Albumin (mg/dl) 4.02 (0.30) 4.03 (0.29) 0.575 3.94 (0.29) 3.99 (0.29) 0.003
*Expressed as percentage of normal pooled plasma.
Data are presented as mean 6 SD.
BP 5 blood pressure; CHF 5 congestive heart failure; CRP 5 C-reactive protein; ECG 5 electrocardiographic; FEV1 5 forced expiratory volume in 1 s; FVC 5 forced
vital capacity; HDL 5 high density lipoprotein; IM 5 intima-media; LDL 5 low density lipoprotein; LV 5 left ventricular.
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pants free of it at baseline and after adjustment for a new
myocardial infarction in participants with baseline coronary
heart disease.
Population-attributable risk. The population-attributable
risk for selected risk factors is shown in Table 5. Prevalent
coronary heart disease was associated with the greatest
population-attributable risk for incident CHF (13.1%),
followed by uncontrolled systolic BP (12.8%), elevated
C-reactive protein (9.7%) and low ankle-arm index (9.2%).
In contrast, the risks attributable to subnormal LV systolic
function (4.1%) and atrial fibrillation (2.2%) were low,
secondary to their low population prevalence.
DISCUSSION
Although the elderly constitute a large proportion of pa-
tients presenting with CHF, few studies have prospectively
evaluated large numbers of community-based elderly sub-
jects by using a wide array of clinical, demographic and
laboratory measures of subclinical disease to determine
clinical and biologic risk factors for CHF. Although sub-
normal LV function was predictive of CHF, the present
study found that CHF in community-based elderly people
was commonly preceded by intact systolic LV function.
Also consistent with the findings of previous studies
(2,3,10,25–27), incident CHF was predicted by male gender
and age, although the strength of gender relations appeared
to be associated with the presence of prevalent coronary
artery disease, and by diminished systolic LV function at
baseline.
Bivariate relations were found between incident CHF
and anthropometric, demographic and functional variables
that have not been widely appreciated. For example, inci-
dent CHF was inversely related to body height, mental
function, educational level and pulmonary function, as well
as directly to measures of subclinical atherosclerosis, inflam-
mation and coagulation. Short stature has been associated
with adverse cardiovascular outcome (28–30). Diminished
mental function may reflect atherosclerotic or hypertensive
brain disease, and hence an increased likelihood of comor-
Table 4. Predictors of Incident Congestive Heart Failure by Coronary Heart Disease by Status at Baseline: Subclinical Disease
Measures Adjusted for Demographic Data, Baseline Disease, Blood Pressure, Lung Function and Blood Markers
Risk Factors
All Subjects
(N 5 4,891, n 5 512)
No CHD at Baseline
(N 5 4,069, n 5 345)
CHD at Baseline
(N 5 821, n 5 167)
RR (95% CI) p Value RR (95% CI) RR (95% CI)
Age (5 years) 1.36 (1.25–1.47) ,0.0001 1.37 (1.24–1.51) 1.35 (1.17–1.55)
Male gender 2.08 (1.57–2.75) ,0.0001 2.19 (1.55–3.08) 1.80 (1.09–2.98)
CHD at baseline 1.58 (1.29–1.94) ,0.0001
Stroke or TIA at baseline 1.52 (1.14–2.02) 0.004 1.56 (1.07–2.27) 1.34 (0.86–2.09)¶
Diabetes status ,0.0001
Glucose $126 mg/dl 1.09 (0.77–1.54) 0.90 (0.59–1.35) 1.63 (0.84–3.16)
History of diabetes 1.74 (1.38–2.19) 1.68 (1.25–2.24) 2.05 (1.39–3.02)
Systolic BP* (20 mm Hg) 1.09 (1.01–1.18) 0.038 1.14 (1.03–1.26) 1.00 (0.99–1.01)¶
FEV1† (liters) 0.66 (0.56–0.78) ,0.0001 0.63 (0.52–0.77) 0.72 (0.53–0.99)
Creatinine .1.4 mg/dl 1.50 (1.17–1.92) 0.001 1.43 (1.03–1.97) 1.66 (1.12–2.46)
CRP quintiles‡ (mg/liters) ,0.0001
#0.95 1.00 (reference) 1.00 (reference) 1.00 (reference)
0.96–1.95 0.95 (0.72–1.25) 0.98 (0.7–1.35) 0.89 (0.52–1.51)
1.96–3.11 1.01 (0.76–1.33) 0.81 (0.56–1.16) 1.52 (0.95–2.43)
3.12–7.37 1.27 (0.95–1.67) 1.11 (0.78–1.59) 1.70 (1.03–2.81)
$7.38 1.91 (1.43–2.57) 2.32 (1.64–3.27) 1.28 (0.71–2.28)
Ankle-arm index #0.9 1.57 (1.26–1.94) ,0.0001 1.43 (1.08–1.90) 1.82 (1.27–2.60)
ECG atrial fibrillation 1.65 (1.11–2.46) 0.014 1.94 (1.23–3.05) 1.15 (0.45–2.95)¶
ECG LV mass quintiles§ ,0.0001
Q2 1.14 (0.86–1.52) 1.11 (0.79–1.55) 1.29 (0.75–2.21)
Q3 1.46 (1.08–1.96) 1.47 (1.02–2.10) 1.45 (0.85–2.49)
Q4 1.88 (1.36–2.59) 1.78 (1.19–2.66) 2.25 (1.27–3.99)
Q5 2.84 (1.98–4.08) 2.92 (1.83–4.66) 2.51 (1.35–4.67)
Major ST-T segment abnormality 1.51 (1.12–2.05) 0.008 1.22 (0.82–1.82)¶ 2.20 (1.34–3.62)
Minor ST-T segment abnormality 1.42 (1.13–1.77) 0.002 1.65 (1.27–2.14) 0.90 (0.58–1.39)¶
Internal carotid .80th percentile 1.26 (1.04–1.53) 0.020 1.23 (0.96–1.58)¶ 1.33 (0.96–1.84)¶
Abnormal LV ejection fraction\ 2.40 (1.71–3.38) ,0.0001 2.84 (1.63–4.93) 2.11 (1.34–3.32)
*Use of antihypertensive medications were included in the model (not shown) so that relative risk for systolic BP could be adjusted for medication use. †Height was included
in model (not shown) to adjust FEV1 for stature. ‡Quintiles were based on congestive heart failure (CHF) cases. §Quintile cutoffs of LV mass by gender (in g) are 120, 135,
147 and 165 for women and 159, 173, 187 and 208 for men. Weight is included in the model (not shown) to adjust for LV mass. \An indicator for missing ejection fraction
was included in the model to maintain the sample size. ¶Variable not statistically significant in this group.
CI 5 confidence interval; N 5 sample size; n 5 cases of CHF; RR 5 relative risk; TIA 5 transient ischemic attack; other abbreviations as in Table 3.
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bid cardiac disease. Low educational level and other markers
of decreased socioeconomic status have been linked to
cardiovascular outcomes (31,32), possibly in relation to
health-damaging behavior (33). Mental function, short
stature and socioeconomic measures did not retain signifi-
cance in multivariate models. This may be a reflection of
their association with biologic predictors, such as coronary
heart disease and hypertension, that are more directly linked
to CHF.
When the relative risk of predictors was interpreted
within the context of the population prevalence of those
predictors (population-attributable risk), prevalent coronary
heart disease, poorly controlled systolic BP and elevated
C-reactive protein were the three leading predictors of
incident CHF in the elderly.
Diastolic versus systolic CHF: role of LV mass. A
principal finding of the study was the presence of intact LV
systolic function commonly preceding the onset of incident
CHF, particularly among women. This finding is consistent
with the findings of others in noting that CHF in the
elderly is commonly “diastolic” (10,25,34,35). Other analy-
ses of the CHS cohort (36) demonstrated a relation between
diastolic filling and subsequent CHF. Moreover, the inde-
pendent association of LV mass with incident CHF has
been reported by others (26) and is consistent with data
from our group (36,37) showing the predictive value of both
diastolic filling velocity and LV mass for subsequent CHF.
Age, gender and race. The present study of an older
population with a greater incidence of CHF supports the
findings of the Framingham investigators (38) and others
(3,39,40) in finding that incident CHF is associated with
male gender and age. Although the predictive value of age
persisted even after adjustment for age-related covariates,
the greater incidence in men, in part explained by greater
prevalent and incident atherosclerosis, is consistent with the
results of the Eastern Finland Surveillance Study (39).
We failed to find greater incidence rates of CHF in
African-American participants. However, the smaller num-
ber of African-American participants relative to white
participants reduces the power of the study to make mean-
ingful comparisons of the effects of race on the incidence of
CHF.
Diabetes and impaired glucose tolerance. Insulin resis-
tance facilitates atherogenesis (41) as well as LV hypertro-
phy (42), both of which may lead to CHF, and diabetes has
been previously associated with CHF (38,43). In our cohort
of elderly individuals, the incidence of CHF was also
substantially higher (approximately twofold) in diabetic men
and women than in nondiabetics. Serum insulin had an
independent predictive value for CHF only in men.
Inflammation. Increased C-reactive protein retained inde-
pendent predictive value for CHF in multivariate models.
Because of its high prevalence in the study group, elevated
C-reactive protein was associated with substantial
population-attributable risk for CHF. Although studies
show that inflammation may be mechanistically associated
with atherogenesis (44,45), the association of C-reactive
protein with incident CHF persisted in models that ad-
justed for clinically prevalent as well as subclinical athero-
sclerotic disease. The increase in C-reactive protein may
reflect a general increase in proinflammatory cytokines,
which are elevated in CHF (46,47) and which have been
implicated in its pathophysiology (48,49).
Pulmonary function and incident CHF. The inverse
relation between FEV1 and incident CHF in this study may
Table 5. Percentage of Incident Congestive Heart Failure in the Population Attributable to
Selected Risk Factors
Risk Factors RR Prevalence (%)
Attributable
Risk (%)
CHD 1.87 17.3 13.08
Systolic BP $140 mm Hg 1.36 40.7 12.78
CRP .7.0 mg/liter 1.93 11.6 9.74
Ankle-arm index #0.9 1.80 12.7 9.22
Internal carotid artery wall thickness $1.88 mm 1.47 19.8 8.51
Diabetes 1.78 11.6 8.30
Low FEV1* 1.35 19.2 6.30
Creatinine .1.4 mg/dl 1.81 8.3 6.30
ECG LVH 2.29 4.5 5.49
Decreased LV function 2.80 2.4 4.14
ST-T segment abnormality 1.67 6.1 3.93
Stroke/TIA 1.48 5.4 2.53
Glucose $126 mg/dl† 1.46 5.5 2.47
ECG atrial fibrillation 2.06 2.1 2.18
*Low FEV1 5 below the lower limit of normal on reference equations predicting FEV1. See text for details. †Among nondiabetic
subjects.
CHD 5 coronary heart disease; LVH 5 left ventricular hypertrophy; TIA 5 transient ischemic attack; other abbreviations
as in Table 3.
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reflect a misclassification of dyspnea due to lung disease as
CHF, as well as the concordance of age-related decreases in
pulmonary function with increases in incident CHF. How-
ever, the relation persisted after adjustment for age and
chronic obstructive lung disease, supporting the previous
findings in the Framingham study (50). In addition, de-
creased FVC may exacerbate the clinical presentation of
CHF. Pulmonary function in the elderly is independently
associated with elevated LV mass, hypertension and isch-
emic cardiac disease (51,52). Multiorgan effects of aging,
possibly encoded at birth (53), may account for pulmonary
as well cardiac dysfunction.
Study limitations. The clinical diagnosis of CHF pre-
sumes that there is pulmonary and/or systemic congestion
consequent to sufficient elevation of left and/or right heart
filling pressure to produce transudation of fluid into the
pulmonary interstitium and alveoli or into the systemic
tissue interstitium. This may occur in the presence or
absence of systolic LV dysfunction. Because it is impractical
in clinical practice or in clinical studies (in particular,
population-based studies) to measure intracardiac filling
pressures, the diagnosis of CHF is based on clinical criteria.
Those used in CHF are similar to those used in the
Framingham study and in other studies. Nonetheless, it is
possible that dyspnea from other causes, such as pulmonary
disease, could be misclassified as CHF. Because participants
with depressed baseline LV systolic function may have
greater mortality associated with CHF, as well as a lower
mean time to death, than those with intact baseline LV
function, survivor effects may have resulted in overestima-
tion of the proportion of participants with intact systolic
function preceding CHF.
Clinical implications. Prevention of CHF in the elderly is
an increasingly important clinical and public health goal for
physicians. The present study underscores the contribution
of poorly controlled systolic BP and of clinically evident
coronary heart disease for incident CHF in community-
based elderly people, many of whom have preserved LV
systolic function. A reduction of systolic BP (54), possi-
bly in relation to a reduction of LV mass (55,56) or left
atrial size (57), or both, with the use of diuretic agents,
beta-blockers (58 – 60) or other therapy, may be helpful
in averting CHF.
Clinical trials of CHF have generally evaluated patients
whose biologic characteristics differ substantially from those
of elderly patients with CHF. Most major clinical trials have
required severe LV dysfunction as a criterion for recruit-
ment and have restricted recruitment to patients substan-
tially younger than those in the present study. Hence, the
optimal therapy for the treatment of CHF remains to be
determined in appropriately designed clinical trials specifi-
cally addressing the particular characteristics of elderly
patients with CHF (61).
Reprint requests and correspondence: Dr. John S. Gottdiener,
Cardiology Research, St. Francis Hospital, 100 Port Washington
Boulevard, Roslyn, New York 11576. E-mail: gottdien@
ziplink.net.
REFERENCES
1. Tighe D, Brest AN. Congestive heart failure in the elderly. Cardiovasc
Clin 1992;22:127–38.
2. Schocken DD, Arrieta MI, Leaverton PE, Ross EA. Prevalence and
mortality rate of congestive heart failure in the United States. J Am
Coll Cardiol 1992;20:301–6.
3. Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart
failure in the community: a study of all incident cases in Olmsted
County, Minnesota, in 1991. Circulation 1998;98:2282–9.
4. Gillum RF. Epidemiology of heart failure in the United States
(editorial). Am Heart J 1993;126:1042–7.
5. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival
after the onset of congestive heart failure in Framingham Heart Study
subjects. Circulation 1993;88:107–15.
6. Fagard R. Reversal of left ventricular hypertrophy (letter). JAMA
1996;276:1636–7.
7. Senni M, Redfield MM. Congestive heart failure in elderly patients.
Mayo Clin Proc 1997;72:453–60.
8. Rich MW. Epidemiology, pathophysiology, and etiology of congestive
heart failure in older adults. J Am Geriatr Soc 1997;45:968–74.
9. Hughes CV, Wong M, Johnson G, Cohn JN. Influence of age on
mechanisms and prognosis of heart failure: the V-HeFT VA Coop-
erative Studies Group. Circulation 1993;87 Suppl VI:VI-111–7.
10. Tresch DD, McGough MF. Heart failure with normal systolic
function: a common disorder in older people. J Am Geriatr Soc
1995;43:1035–42.
11. Fried L, Borhani N, Enright P, et al., for the CHS Collaborative
Research Group. The cardiovascular health study: design and ratio-
nale. Ann Epidemiol 1991;1:263–76.
12. Psaty B, Kuller L, Bild D, et al. Methods of assessing prevalent
cardiovascular disease in the Cardiovascular Health Study. Ann
Epidemiol 1998;5:270–7.
13. Ives D, Fitzpatrick A, Bild D, et al. Surveillance and ascertainment of
cardiovascular events: the Cardiovascular Health Study. Ann Epide-
miol 1995;4:278–85.
14. Rautaharju P, Calhoun H, Chaitman B. Novacode serial ECG
classification system for clinical trials and epidemiological studies. J
Electrocardiol 1992;24:163–72.
15. Rautaharju PM, Manolio TA, Siscovick D, et al., for the Cardiovas-
cular Health Study Collaborative Research Group. Utility of new
electrocardiographic models for left ventricular mass in older adults.
Hypertension 1996;28:8–15.
16. Rautaharju PM, Manolio TA, Siscovick D, et al., for the CHS
Collaborative Research Group. Classification accuracy of electrocar-
diographic criteria for left ventricular hypertrophy in normal weight
and overweight older adults: the Cardiovascular Health Study. Ann
Noninvas Electrocardiol 1996;1:121–31.
17. Blackburn H, Keys A, Simonson E, Rautaharju P, Punsar S. The
electrocardiogram in population studies: a classification system. Cir-
culation 1960;21:1160–75.
18. Furberg C, Manolio T, Psaty B, et al. Major ECG abnormalities in
persons aged 65 years and older (the Cardiovascular Health Study).
Am J Cardiol 1992;69:1329–35.
19. Gardin JM, Siscovick D, Anton-Culver H, et al. Sex, age, and disease
affect echocardiographic left ventricular mass and systolic function in
the free-living elderly (the Cardiovascular Health Study). Circulation
1995;91:1739–48.
20. O’Leary DH, Polak JF, Kronmal RA, et al., for the Cardiovascular
Health Study Collaborative Research Group. Thickening of the
carotid wall: a marker for atherosclerosis in the elderly? Stroke
1996;27:224–31.
21. Folkstein MF, Folkstein SE, McHugh PR. Mini-mental state. J Psy-
chiatr Res 1975;12:189–98.
22. Hennekens C, Buring J. Epidemiology in Medicine. Boston: Little,
Brown, 1987.
23. Enright PL, Kronmal RA, Higgins M, Schenker M, Haponik EF.
1636 Gottdiener et al. JACC Vol. 35, No. 6, 2000
Congestive Heart Failure in the Elderly May 2000:1628–37
Spirometry reference value for women and men 65 to 85 years of age.
Am Rev Respir Dis 1993;47:125–33.
24. Enright PL, Arnold A, Manolio TA, Kuller LH. Spirometry reference
values for healthy elderly blacks: the Cardiovascular Health Study.
Chest 1996;110:1415–24.
25. Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and
prognosis of diastolic heart failure: an epidemiologic perspective. J Am
Coll Cardiol 1995;26:1565–74.
26. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progres-
sion from hypertension to congestive heart failure. JAMA 1996;275:
1557–62.
27. Cowie MR, Wood DA, Coats AJS, et al. Incidence and aetiology of
heart failure. Eur Heart J 1999;20:421–8.
28. Cook NR, Hebert PR, Satterfield S, Taylor JO, Buring JE, Hennekens
CH. Height, lung function, and mortality from cardiovascular disease
among the elderly. Am J Epidemiol 1994;139:1066–76.
29. Hebert PR, Rich-Edwards JW, Manson JE, et al. Height and
incidence of cardiovascular disease in male physicians. Circulation
1993;88:1437–43.
30. Leon DA, Smith GD, Shipley M, Strachan D. Adult height and
mortality in London: early life, socioeconomic confounding, or shrink-
age? J Epidemiol Community Health 1995;49:5–9.
31. Salonen JT. Socioeconomic status and risk of cancer, cerebral stroke,
and death due to coronary heart disease and any disease: a longitudinal
study in Eastern Finland. J Epidemiol Community Health 1981;36:
294–7.
32. Antonovsky A. Social class and the major cardiovascular diseases.
J Chronic Dis 1982;21:65–106.
33. Alexander M, Grumbach K, Selby J, Brown AF, Washington E.
Hospitalization for congestive heart failure: explaining racial differ-
ences. JAMA 1995;274:1037–42.
34. Vasan RS, Benjamin EJ, Levy D. Congestive heart failure with normal
left ventricular systolic function: clinical approaches to the diagnosis
and treatment of diastolic heart failure. Arch Intern Med 1996;156:
146–57.
35. Mosterd A, Hoes AW, de Bruyne MC, et al. Prevalence of heart
failure and left ventricular dysfunction in the general population: the
Rotterdam Study. Eur Heart J 1999;20:447–55.
36. Aurigemma GP, Gottdiener JS, Shemanski L, Gardin JM, Kitzman
D. Predictive value of systolic and diastolic function for incident
congestive heart failure in the elderly: the Cardiovascular Health Study
(abstr). Circulation 1998;98:I-1193.
37. Gardin J, McClelland R, Kitzman D, et al. M-mode echocardio-
graphic predictors of four-year incidence of coronary heart disease,
stroke, congestive heart failure, and mortality in an elderly cohort: the
Cardiovascular Health Study. Circulation 1999;100:I-581.
38. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart
failure: the Framingham Study. J Am Coll Cardiol 1993;22 Suppl:
6A–13A.
39. Remes J, Reunanen A, Aromaa A, Pyorala K. Incidence of heart
failure in eastern Finland: a population-based surveillance study. Eur
Heart J 1992;13:588–93.
40. Kimmelstiel CD, Konstam MA. Heart failure in women. Cardiology
1995;86:304–9.
41. Krolewski AS, Warram JH, Valsania P, et al. Evolving natural history
of coronary artery disease in diabetes mellitus. Am J Med 1991;90
Suppl 2A:56S–61S.
42. Sasson Z, Rasooly Y, Bhesania T, Rasooly I. Insulin resistance is an
important determinant of left ventricular mass in the obese. Circula-
tion 1993;88:1431–6.
43. Andersson B, Waagstein F. Spectrum and outcome of congestive heart
failure in a hospitalized population. Am Heart J 1993;126:632–40.
44. Tracy RP, Lemaitre RN, Psaty BM, et al. Relationship of C-reactive
protein to risk of cardiovascular disease in the elderly: results from the
Cardiovascular Health Study and the Rural Health Promotion Project.
Arterioscler Thromb Vasc Biol 1997;17:1121–7.
45. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH.
Inflammation, aspirin, and the risk of cardiovascular disease in appar-
ently healthy men. N Engl J Med 1997;336:973–9.
46. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated
circulating levels of tumor necrosis factor in congestive heart failure.
N Engl J Med 1990;323:236–41.
47. Dibbs Z. Cytokines in heart failure: pathogenetic mechanisms and
potential treatment. Proc Assoc Am Physiol 1999;111:423–8.
48. Tsutamoto T, Hisanaga T, Wada A, et al. Interleukin-6 spillover in
the peripheral circulation increases with the severity of heart failure,
and the high plasma level of interleukin-6 is an important prognostic
predictor in patients with congestive heart failure. J Am Coll Cardiol
1998;31:391–8.
49. Lommi J, Pulkki K, Koskinen P, et al. Haemodynamic, neuroendo-
crine and metabolic correlates of circulating cytokine concentrations in
congestive heart failure. Eur Heart J 1997;18:1620–5.
50. Kannel WB, Seidman JM, Fercho W, Castelli WP. Vital capacity and
congestive heart failure: the Framingham Study. Circulation 1974;49:
1160–6.
51. Enright PL, Kronmal RA, Smith VE, Gardin JM, Schenker MB,
Manolio TA. Reduced vital capacity in elderly persons with hyperten-
sion, coronary heart disease, or left ventricular hypertrophy: the
Cardiovascular Health Study. Chest 1995;107:28–35.
52. Marcus EB, Curb JD, MacLean CJ, Reed DM, Yano K. Pulmonary
function as a predictor of coronary heart disease. Am J Epidemiol
1989;129:97–104.
53. Barker DJ. Fetal origins of coronary heart disease. BMJ 1995;311:
171–4.
54. Kostis JB, Davis BR, Cutler J, et al., for the SHEP Cooperative
Research Group. Prevention of heart failure by antihypertensive drug
treatment in older persons with isolated systolic hypertension. JAMA
1997;278:212–6.
55. Levy D, Salomon M, D’Agostino RB, Belanger AJ, Kannel WB.
Prognostic implications of baseline electrocardiographic features and
their serial changes in subjects with left ventricular hypertrophy.
Circulation 1994;90:1786–93.
56. Verdecchia P, Schillaci G, Borgioni C, et al. Prognostic significance of
serial changes in left ventricular mass in essential hypertension.
Circulation 1998;97:48–54.
57. Gottdiener J, Reda D, Williams D, Materson B, Cushman W,
Anderson R, for the Department of Veterans Affairs Cooperative
Study group on Antihypertensive Agents. Effect of single-drug therapy
on reduction of left atrial size in mild to moderate hypertension:
comparison of six antihypertensive agents. Circulation 1998;98:
140–8.
58. Gottdiener J, Reda D, Massie BM, Materson BJ, Williams DW,
Anderson RJ, for the Department of Veterans Affairs Cooperative
Study Group on Antihypertensive Agents. Effect of single-drug
therapy on reduction of left ventricular mass in mild to moderate
hypertension: comparison of six antihypertensive agents. Circulation
1997;95:2007–14.
59. Papademetriou V, Gottdiener JS, Narayan P, et al., for the Isradipine
Study Group. Hydrochlorothiazide is superior to isradipine for reduc-
tion of left ventricular mass: results of a multicenter trial. J Am Coll
Cardiol 1997;30:1802–8.
60. Ofili EO, Cohen JD, St. Vrain JA, et al. Effect of treatment of isolated
systolic hypertension on left ventricular mass. JAMA 1998;279:778–
80.
61. Mosterd A. Heart failure in the population at large: news from the real
world (editorial). Eur Heart J 1999;20:398–9.
1637JACC Vol. 35, No. 6, 2000 Gottdiener et al.
May 2000:1628–37 Congestive Heart Failure in the Elderly
